Back to search

University of Leeds

Investigating Pim kinase inhibition as a novel anti-thrombotic endothelium targeting strategy

Abstract

dc:description.abstract

Background and Purpose: Atherothrombosis, a key driver of cardiovascular disease, involves complex interactions between endothelial cells and circulating platelets. While current anti-platelet therapies are effective, they offer limited secondary prevention and are associated with significant adverse effects. Pim kinases have emerged as novel regulators of platelet function and thrombosis and are expressed in endothelial cells. Their inhibition may therefore offer additional therapeutic benefit on thrombosis. This study investigates the effects of PIM1 deletion in mice and pan-Pim kinase inhibitors AZD1208, PIM447, and TP3654 on human coronary artery endothelial cell (HCAEC) function and their potential to modulate thrombogenic responses. Methodology: Constitutive PIM1-/- mice were used to investigate the impact of PIM1 deletion on coagulation parameters and endothelial phenotype and function. Inhibitor studies were performed to investigate the effect of Pim kinase inhibition on coronary arterial endothelial function. HCAECs were treated with AZD1208, PIM447, and TP3654 (0.1–10µM) and endothelial survival, viability, migration, and angiogenesis assessed using LDH release, MTS assay, wound healing, and tube formation assays, respectively. Expression and release of inflammatory and thrombotic markers were quantified via RNA-Seq, RT-qPCR, and a Luminex multiplex assay. Finally, the impact of Pim inhibitor-conditioned media on platelet adhesion and coagulation was evaluated using in vitro thrombosis and clotting assays. Key Results: PIM1 deletion in mice was associated with a decrease in PIM2 and PIM3 gene expression in endothelial cells, along with decreased endothelial angiogenesis, and a delay in intrinsic clotting time. In human endothelial cell experiments, expression of the three Pim kinase isoforms was upregulated by TNFα and IL-6 treatment, and Pim kinase inhibitor treatment did not impair HCAEC viability, proliferation, or migration, indicating a lack of cytotoxicity at physiologically achievable concentrations. However, angiogenic capacity of HCAECs was significantly reduced. RNA-Seq analysis demonstrated alterations in expression of endothelial mediators of inflammation and thrombosis following 24-hour inhibitor treatment. Additionally, platelet and leukocyte deposition on confluent treated HCAECs was attenuated under flow and releasate from treated HCAECs delayed intrinsic coagulation pathways. Conclusion and Implications: Pan Pim kinase inhibitors exhibit anti-inflammatory and anti-thrombotic effects in HCAECs without compromising endothelial integrity or function, supporting further investigation into Pim kinase inhibition as a novel strategy for the prevention of atherothrombosis.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Karim, Eima Rehmana
Advisors dc:contributor.advisor
  • Unsworth, Amanda
  • Ariens, Robert
  • Feller, Timea
ORCID person:identifier.orcid

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Dc Identifier Grantnumber
FS/PhD/22/29256

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Karim, Eima Rehmana. Investigating Pim kinase inhibition as a novel anti-thrombotic endothelium targeting strategy. doctoral thesis, University of Leeds, 2026.